Related references
Note: Only part of the references are listed.MRI in multiple sclerosis: a review of the current literature
Antonia Ceccarelli et al.
CURRENT OPINION IN NEUROLOGY (2012)
Association between pathological and MRI findings in multiple sclerosis
Massimo Filippi et al.
LANCET NEUROLOGY (2012)
Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab
Martin Gunnarsson et al.
ANNALS OF NEUROLOGY (2011)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Treatment of multiple sclerosis: current concepts and future perspectives
Dorothea Buck et al.
JOURNAL OF NEUROLOGY (2011)
Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis
M. Axelsson et al.
JOURNAL OF NEUROLOGY (2011)
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
Mohsen Khademi et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
MRI as an outcome in multiple sclerosis clinical trials
M. Daumer et al.
NEUROLOGY (2009)
Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS
F. Sellebjerg et al.
NEUROLOGY (2009)
Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis
C. E. Teunissen et al.
NEUROLOGY (2009)
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
C. E. Teunissen et al.
NEUROLOGY (2009)
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology
Roberta Magliozzi et al.
BRAIN (2007)
Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis
Lisa K. Peterson et al.
JOURNAL OF NEUROIMMUNOLOGY (2007)
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2007)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Multiple sclerosis severity score -: Using disability and disease duration to rate disease severity
RHSR Roxburgh et al.
NEUROLOGY (2005)
Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis
B Serafini et al.
BRAIN PATHOLOGY (2004)
Neurofilament and glial fibrillary acidic protein in multiple sclerosis
N Norgren et al.
NEUROLOGY (2004)
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS
C Malmeström et al.
NEUROLOGY (2003)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
JA Cohen et al.
NEUROLOGY (2002)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.
LD Jacobs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
